Press coverage about Davita (NYSE:DVA) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Davita earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.5217289786462 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- DaVita Physician Solutions Makes Its First Big Investment in New Technology from Epic (finance.yahoo.com)
- Davita (DVA) Stock Rating Reaffirmed by Bank of America (americanbankingnews.com)
- DaVita Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference (finance.yahoo.com)
- DaVita Inc. (DVA) – Healthcare stock under Review – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Where to look at selling opportunities on DaVita Inc. (DVA) – Wall Street Morning (wallstreetmorning.com)
Shares of Davita (NYSE:DVA) traded down $0.90 during trading on Friday, hitting $79.13. The stock had a trading volume of 1,440,371 shares, compared to its average volume of 1,714,989. The firm has a market capitalization of $14,500.00, a P/E ratio of 30.32, a PEG ratio of 15.06 and a beta of 0.96. Davita has a 1-year low of $52.51 and a 1-year high of $80.71. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40.
Davita (NYSE:DVA) last posted its earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.13). The business had revenue of $3.92 billion for the quarter, compared to analysts’ expectations of $3.91 billion. Davita had a negative return on equity of 17.43% and a negative net margin of 4.39%. Davita’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.95 EPS. analysts forecast that Davita will post 3.42 EPS for the current year.
Davita announced that its board has authorized a stock repurchase program on Tuesday, October 10th that allows the company to buyback $1.50 billion in shares. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
DVA has been the subject of a number of analyst reports. Wolfe Research raised Davita from a “market perform” rating to an “outperform” rating in a research report on Monday, October 23rd. Bank of America lowered their price objective on Davita from $75.00 to $66.00 and set a “neutral” rating for the company in a research report on Wednesday, November 8th. JPMorgan Chase & Co. downgraded Davita from a “neutral” rating to an “underweight” rating in a research report on Monday, October 9th. Zacks Investment Research downgraded Davita from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Raymond James Financial raised Davita from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $65.00 to $84.00 in a research report on Thursday, December 7th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $78.22.
In related news, CEO Javier Rodriguez sold 22,532 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $67.48, for a total transaction of $1,520,459.36. Following the completion of the sale, the chief executive officer now owns 210,317 shares in the company, valued at $14,192,191.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Charles Berg sold 7,048 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $69.24, for a total value of $488,003.52. Following the sale, the insider now owns 5,359 shares of the company’s stock, valued at approximately $371,057.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 117,937 shares of company stock valued at $8,028,379. 2.00% of the stock is owned by company insiders.
WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2018/01/12/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-davita-dva-stock-price.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.